CRYPTO 5%

Research-grade peptides. Shipped same day in Bangkok.

06 / CJC-1295

CJC-1295

Available as LUNEA

Molecular profile
Sequence H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Formula C152H252N44O42
Class No DAC / Modified GRF(1-29)

A synthetic tetrasubstituted analog of the first 29 residues of GHRH. Peptheos supplies the no-DAC form, also called Modified GRF(1-29): the tetrasubstituted hGRF(1-29) backbone with a C-terminal amide and no DAC linker, molecular weight approximately 3367.9 g/mol. Most product sold online as plain “CJC-1295” is this peptide. A certificate of analysis is the only way to know which molecule is in a vial.

Design and stability of the analog

A 1994 structure-activity study examined how growth hormone-releasing factor is inactivated in plasma, identifying dipeptidyl peptidase IV cleavage between residues 2 and 3, deamidation at position 8, and oxidation at position 27. The substitutions that answer those three routes, together with Ala at position 15, are the four that define Modified GRF(1-29). The study reported enhanced stability and potency for the resulting analogues relative to the unmodified sequences.

Pharmacokinetics of the position-2 substitution

A 1994 study in normal men examined GRF(1-29)-NH2 carrying D-Ala at position 2 against the unsubstituted peptide, and reported an increased half-life and decreased metabolic clearance for the substituted form. That study examined the single position-2 substitution, not the full tetrasubstituted analog, so it speaks to one of the four changes rather than to the molecule as a whole.

The parent peptide, GRF(1-29)

A 1992 study in older men administered GRF(1-29), also known as sermorelin, twice daily and reported dose-related increases in growth hormone and insulin-like growth factor I. This examined the parent peptide itself rather than the substituted analog, so it describes the sequence Modified GRF(1-29) is built on and not that compound.

Peer-reviewed references

  • Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides. 1994;15(3):489-495. doi.org/10.1016/0196-9781(94)90211-9
  • Soule S, et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994;79(4):1208-1211. doi.org/10.1210/jcem.79.4.7962295
  • Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. doi.org/10.1210/jcem.75.2.1379256

Library

Research and Whitepapers

CJC-1295: One Name, Two Molecules

CJC-1295 is a synthetic analog of growth hormone-releasing hormone. The name covers two different molecules, one carrying an albumin-binding complex and one without, and the distinction changes both the chemistry and the half-life. Reading the research starts with telling them apart.

For research purposes only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.